Search

Your search keyword '"Steurer M"' showing total 155 results
Start Over Author "Steurer M" Publication Year Range Last 10 years
155 results on '"Steurer M"'

4. Robust Control of a Medium Voltage AC/DC Testbed

Author

null Tschritter, C, null Johnston, A, null Vu, L, null Nguyen, T, null Wetz, D, null Vu, T, null Langston, J, null Ravindra, H, null Stanovich, M, null Schoder, K, null Steurer, M, null Schegan, C, and null Heinzel, J

Published
2022

14. Retrospective cohort study of all deaths among infants born between 22 and 27 completed weeks of gestation in Switzerland over a 3-year period

Author

Berger, T M, Steurer, M A, Bucher, H U, Fauchère, J C, Adams, M, Pfister, R E, Baumann-Hölzle, R, Bassler, D, Swiss Neonatal End-of-Life Study Group, University of Zurich, and Berger, T M

Subjects
Parents, Pediatrics, medicine.medical_specialty, Decision Making, 610 Medicine & health, Infant, Premature, Diseases, 2700 General Medicine, live birth, 03 medical and health sciences, Advance Care Planning, 0302 clinical medicine, end-of-life decision-making, 030225 pediatrics, Intensive care, Intensive Care Units, Neonatal, Infant Mortality, medicine, Humans, 030212 general & internal medicine, Retrospective Studies, ddc:618, business.industry, extremely low gestational age neonates, Research, Delivery room, Infant, Newborn, Gestational age, Infant, Retrospective cohort study, Paediatrics, General Medicine, 10027 Clinic for Neonatology, Life support, Infant, Extremely Premature, Practice Guidelines as Topic, Quality of Life, Gestation, stillbirth, Level iii, Live birth, business, Medical Futility, Switzerland, redirection of care
Abstract

Objectives The aim of this research is to assess causes and circumstances of deaths in extremely low gestational age neonates (ELGANs) born in Switzerland over a 3-year period. Design Population-based, retrospective cohort study. Setting All nine level III perinatal centres (neonatal intensive care units (NICUs) and affiliated obstetrical services) in Switzerland. Patients ELGANs with a gestational age (GA)

Published
2017

21. Chromothripsis in acute myeloid leukemia: Biological features and impact on survival

Author

Fontana, M C, primary, Marconi, G, additional, Feenstra, J D M, additional, Fonzi, E, additional, Papayannidis, C, additional, di Rorá, A G L, additional, Padella, A, additional, Solli, V, additional, Franchini, E, additional, Ottaviani, E, additional, Ferrari, A, additional, Baldazzi, C, additional, Testoni, N, additional, Iacobucci, I, additional, Soverini, S, additional, Haferlach, T, additional, Guadagnuolo, V, additional, Semerad, L, additional, Doubek, M, additional, Steurer, M, additional, Racil, Z, additional, Paolini, S, additional, Manfrini, M, additional, Cavo, M, additional, Simonetti, G, additional, Kralovics, R, additional, and Martinelli, G, additional

Published
2017
Full Text
View/download PDF

22. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

Author

Cines, DB, Wasser, J, Rodeghiero, F, Chong, BH, Steurer, M, Provan, D, Lyons, R, Garcia-Chavez, J, Carpenter, N, Wang, X, Eisen, M, Cines, DB, Wasser, J, Rodeghiero, F, Chong, BH, Steurer, M, Provan, D, Lyons, R, Garcia-Chavez, J, Carpenter, N, Wang, X, and Eisen, M

Abstract

© 2017 Ferrata Storti Foundation. Primary immune thrombocytopenia is an autoimmune disorder characterized by increased platelet destruction and insufficient platelet production without another identified underlying disorder. Splenectomy may alter responsiveness to treatment and/or increase the risk of thrombosis, infection, and pulmonary hypertension. The analysis herein evaluated the safety and efficacy of the thrombopoietin receptor agonist romiplostim in splenectomized and nonsplenectomized adults with primary immune thrombocytopenia. Data were pooled across 13 completed clinical studies in adults with immune thrombocytopenia from 2002-2014. Adverse event rates were adjusted for time of exposure. Results were considered different when 95% confidence intervals were non-overlapping. Safety was analyzed for 1111 patients (395 splenectomized; 716 nonsplenectomized) who received romiplostim or control (placebo or standard of care). At baseline, splenectomized patients had a longer median duration of immune thrombocytopenia and a lower median platelet count, as well as a higher proportion with >3 prior immune thrombocytopenia treatments versus nonsplenectomized patients. In each treatment group, splenectomized patients used rescue medications more often than nonsplenectomized patients. Platelet response rates (≥50×109/L) for romiplostim were 82% (310/376) for splenectomized and 91% (592/648) for nonsplenectomized patients (P<0.001 by Cochran-Mantel-Haenszel test). Platelet responses were stable over time in both subgroups. Exposure-adjusted adverse event rates were higher for control versus romiplostim for both splenectomized (1857 versus 1226 per 100 patient-years) and nonsplenectomized patients (1052 versus 852 per 100 patient-years). In conclusion, responses to romiplostim were seen in both splenectomized and nonsplenectomized patients, and romiplostim was not associated with an increase in the risk of adverse events in splenectomized patients. clinical-trials.gov I

Published
2017

23. Self-guided exploration of virtual learning spaces

Author

Reiners, T., Wood, L.C., Teräs, M., Teräs, H., Gregory, S., Chang, V., Steurer, M., McDonald, T., Fardinpour, A., Reiners, T., Wood, L.C., Teräs, M., Teräs, H., Gregory, S., Chang, V., Steurer, M., McDonald, T., and Fardinpour, A.

Abstract

Virtual learning spaces provide the opportunity to create authentic, immersive and high-fidelity experiences for learners; often enhanced with new technology to increase the interaction and perception with the learning space. Instead of creating mock-ups in classrooms, educators are able to recreate a controlled replica of the real world, i.e. scenarios and situations can be created that are difficult or impossible to achieve otherwise. However, an unrestricted and unsupervised exploration imposes challenges to monitor the learner, offer supportive guidance and provide formative feedback. Preliminary studies demonstrated that different approaches are able to engage the learner, create an intrinsic motivation and therefore provide curiosity to drive the self-paced learning; yet the use-case-based exploration is not transferred to a framework including a comprehensive tool for education. In this chapter, we demonstrate the prototype of the nDiVE framework, which combines authentic education, gamification, emerging technology and design principles used in the game industry to create an engaging learning space for students and workers.

Published
2017

24. Self-guided exploration of virtual learning spaces

Author

Reiners, Torsten, Wood, Lincoln, Teräs, M., Teräs, H., Gregory, S., Chang, V., Steurer, M., McDonald, T., Fardinpour, A., Reiners, Torsten, Wood, Lincoln, Teräs, M., Teräs, H., Gregory, S., Chang, V., Steurer, M., McDonald, T., and Fardinpour, A.

Published
2017

32. High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis

Author

Schwarz, J., primary, Werner, C., additional, Steurer, M., additional, Spengler, U., additional, Wedemeyer, H., additional, von Hahn, T., additional, Stremmel, W., additional, Pathil-Warth, A., additional, Berg, T., additional, Engelmann, C., additional, Seybold, U., additional, Schott, E., additional, Blessin, U., additional, Malek, N., additional, Lauer, U., additional, and Berg, C., additional

Published
2017
Full Text
View/download PDF

33. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study

Author

Ninkovic, M., Fiegl, M., Mian, M., Mondello, P., Kocher, F., Waldthaler, C., Verdorfer, I., Steurer, M., Gastl, G., and Andreas Pircher

Subjects
Bendamustine, chemotherapy, chronic lymphocytic leukemia (CLL), immunotherapy, rituximab, Antineoplastic Agents, Leukemia, Lymphocytic, Chronic, B-Cell, Disease-Free Survival, Cohort Studies, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Multivariate Analysis, Bendamustine Hydrochloride, Humans, Rituximab
Abstract

Bendamustine is an established treatment option in chronic lymphocytic leukemia (CLL) and frequently used in Austria and Italy. Therefore, we analyzed 100 unselected, consecutive patients with CLL (treatment-naïve and relapsed/refractory) receiving bendamustine in a real-life setting. Most patients were treated with bendamustine in combination with rituximab (BR). However, bendamustine monotherapy was additionally evaluated. Patients treated with BR had a significantly higher overall response rate of 76% (complete response=22%) when compared to those treated solely with bendamustine (overall response rate=50%; complete response=13%). Overall survival (OS) and progression -ree survival (PFS) were significantly lower in the bendamustine-treated group (OS=14.3 months; PFS=8.3 months) compared to the BR group (OS=42.7; PFS=22.5 months; both p0.001). In multivariate analysis, patients with a good cytogenetic risk and those receiving BR had a significantly better OS. Grade 3/4 hematological complications were seen in 32% of the patients. Hence, bendamustine, especially in combination with rituximab, is an effective therapy with manageable toxicity for non-selected patients with CLL including those pre-treated with fludarabine and the elderly.

Published
2015

34. QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY

Author

Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M., van Dongen, J., Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M., and van Dongen, J.

Published
2016

37. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Author

Deshmukh C.D., Offner F., Van Den Neste E.W., Wu K.L., Van Hoof A., Maiolino A., Pinczowski H., Zanichelli M.A., Pereira J., Larratt L., Spaner D., Howson-Jan K., Chen C.I., Cantin G., Fernandez L.A., Fraser G., Mayer J., Trneny M., Jebavy L., Bordessoule D., Lamy T., Milpied N., Truchan-Graczyk M., Eghbali H., Karsenti J.-M., Celigny P.S., Mans L., Cazin B., Gyan E., Lepretre S., Bergmann L., Tsionos K., Lokeshwar N.M., Agarwal M.B., Ross C.R., Narayanan G., Raina V., Bondarde S.A., Shah B.A., Bairey O., Tikva P., Shvidel L., Ambrosetti A., Rossi P.G.B., Angelucci E., Carella A.M., Massaia M., Zinzani P.L., Caligaris-Cappio F., Foa R., Gaidano G., della Carita A.O.M., Leone G., Santoro A., Griskevicius L., Jurgutis R., Baker B.W., Hawkins T., Corbett G.M., Ganly P., D'Souza A.B., Deptala A., Holowiecki J., Kloczko J., Skotnicki A., Zdziarska B., Kyrcz-Krzemien S., Dmoszynska A., Moreira I., Pereira A.P., Colita A., Moicean A.D., Vasilica M., Danaila C., Gheorghita E., Pavlov V.V., Rossiev V.A., Konstantinova T., Samoilova O.S., Novgorod N., Shelekhova T., Zaritsky A.Y., Abdulkadyrov K.M., Zyuzgin I.S., Pristupa A.S., Loscertales J., Vidal J.B., de Mallorca P., Gonzalez M., Ortuno F., Giraldo P., Nathwani A., Agrawal S.G., Rule S., Dearden C.E., Bloor A.J., Haynes A., Singer C., Boclek R.G., Bosserman L.D., Chan D., Davidson S.J., Dichmann R.A., Farber C., Hart L., Hermann R., Hu E., Janakiraman N., Jonas W., Liem K.D., Mcintyre R.E., O'Brien S., Patel G., Rado T., Schilder R., Smith S.E., Stock W., Turturro F., Venugopal P., Anderson T.C., Berry W., Boyd T.E., Byrd J., Cooper M., Flinn I., Gersh R., Gordon D., Guzley G.J., Wilks S.T., Klein A., Krauss J.C., Lister J., Mandell L., Molina A., Cooper B., Pendergrass K.B., Reeder C., Savin M.A., Spitzer G., Tuscano J.M., vanDeventer H., Eradat H.A., Masood A., Mena R., Awan F.T., Hillmen P., Hellmann A., Robak T., Hughes S.G., Trone D., Shannon M., Flinn I.W., Byrd J.C., Riveros D., Pavlovsky S., Iastrebner C.M., Carney D.A., Deveridge S., Durrant S., Hahn U.H., Hertzberg M., Leahy M.F., Ma D., Marlton P., Mulligan S., Opat S.S., Tiley C., Wickham N.W., Cannell P., Gatalano J., Catalano J., Cull G., To L.B., Hopfinger G., Jager U., Linkesch W., Petzer A., Schwarzmeier J., Steurer M., Greil R., Bememan Z., Bosly A., Bron D., Janssens A., Deshmukh C.D., Offner F., Van Den Neste E.W., Wu K.L., Van Hoof A., Maiolino A., Pinczowski H., Zanichelli M.A., Pereira J., Larratt L., Spaner D., Howson-Jan K., Chen C.I., Cantin G., Fernandez L.A., Fraser G., Mayer J., Trneny M., Jebavy L., Bordessoule D., Lamy T., Milpied N., Truchan-Graczyk M., Eghbali H., Karsenti J.-M., Celigny P.S., Mans L., Cazin B., Gyan E., Lepretre S., Bergmann L., Tsionos K., Lokeshwar N.M., Agarwal M.B., Ross C.R., Narayanan G., Raina V., Bondarde S.A., Shah B.A., Bairey O., Tikva P., Shvidel L., Ambrosetti A., Rossi P.G.B., Angelucci E., Carella A.M., Massaia M., Zinzani P.L., Caligaris-Cappio F., Foa R., Gaidano G., della Carita A.O.M., Leone G., Santoro A., Griskevicius L., Jurgutis R., Baker B.W., Hawkins T., Corbett G.M., Ganly P., D'Souza A.B., Deptala A., Holowiecki J., Kloczko J., Skotnicki A., Zdziarska B., Kyrcz-Krzemien S., Dmoszynska A., Moreira I., Pereira A.P., Colita A., Moicean A.D., Vasilica M., Danaila C., Gheorghita E., Pavlov V.V., Rossiev V.A., Konstantinova T., Samoilova O.S., Novgorod N., Shelekhova T., Zaritsky A.Y., Abdulkadyrov K.M., Zyuzgin I.S., Pristupa A.S., Loscertales J., Vidal J.B., de Mallorca P., Gonzalez M., Ortuno F., Giraldo P., Nathwani A., Agrawal S.G., Rule S., Dearden C.E., Bloor A.J., Haynes A., Singer C., Boclek R.G., Bosserman L.D., Chan D., Davidson S.J., Dichmann R.A., Farber C., Hart L., Hermann R., Hu E., Janakiraman N., Jonas W., Liem K.D., Mcintyre R.E., O'Brien S., Patel G., Rado T., Schilder R., Smith S.E., Stock W., Turturro F., Venugopal P., Anderson T.C., Berry W., Boyd T.E., Byrd J., Cooper M., Flinn I., Gersh R., Gordon D., Guzley G.J., Wilks S.T., Klein A., Krauss J.C., Lister J., Mandell L., Molina A., Cooper B., Pendergrass K.B., Reeder C., Savin M.A., Spitzer G., Tuscano J.M., vanDeventer H., Eradat H.A., Masood A., Mena R., Awan F.T., Hillmen P., Hellmann A., Robak T., Hughes S.G., Trone D., Shannon M., Flinn I.W., Byrd J.C., Riveros D., Pavlovsky S., Iastrebner C.M., Carney D.A., Deveridge S., Durrant S., Hahn U.H., Hertzberg M., Leahy M.F., Ma D., Marlton P., Mulligan S., Opat S.S., Tiley C., Wickham N.W., Cannell P., Gatalano J., Catalano J., Cull G., To L.B., Hopfinger G., Jager U., Linkesch W., Petzer A., Schwarzmeier J., Steurer M., Greil R., Bememan Z., Bosly A., Bron D., and Janssens A.

Abstract

Summary: Lumiliximab is a chimeric monoclonal antibody that targets CD23 on the surface of chronic lymphocytic leukaemia (CLL) B-cells. Early phase clinical studies with lumiliximab alone and in combination with fludarabine, cyclophosphamide and rituximab (FCR) established its potential efficacy and tolerability. The 152CL201 trial [Lumiliximab with fludarabine, cyclophosphamide and rituximab (FCR) versus FCR alone in subjects with relapsed CLL; LUCID] was a phase 2/3, randomized (1:1), open-label, multicentre study of lumiliximab in combination with FCR versus FCR alone in patients with relapsed CLL. Six hundred and twenty-seven patients were randomized to either arm. Overall the combination of lumiliximab with FCR was not significantly better than FCR alone (overall response rate 71% vs. 72%, complete response rate 16% vs. 15%, median progression-free survival 24.6 vs. 23.9 months respectively, for FCR with and without lumiliximab). There was a slightly increased incidence of adverse events with lumiliximab but these increases did not appear to lead to differences in eventual outcomes. An interim analysis failed to show sufficient efficacy of the combination of lumiliximab with FCR. The study was therefore stopped early for lack of efficacy. Despite the eventual outcome, the LUCID trial is one of the largest studies that provides valuable insight into the efficacy and tolerability of FCR as a therapeutic option for patients with relapsed CLL.Copyright © 2014 John Wiley & Sons Ltd.

Published
2015

38. Treatment of refractory hairy cell leukemia by BRAF-inhibition

Author

Dietrich, S., Pircher, A., Andrulis, M. A., Peyrade, F., Wendtner, C. -M, Gaehler, A., Follows, G., Dyer, M., Elter, T., Zeiser, R., Herrmann, M., Herold, M., Dearden, C., Haferlach, T., Hallek, M., Huellein, J., Matutes, E., Duerig, J., von Kalle, C., Glimm, H., Froehling, S., Abdel-Wahab, O., Hutter, B., Steurer, M., Ho, A., Zenz, T., Dietrich, S., Pircher, A., Andrulis, M. A., Peyrade, F., Wendtner, C. -M, Gaehler, A., Follows, G., Dyer, M., Elter, T., Zeiser, R., Herrmann, M., Herold, M., Dearden, C., Haferlach, T., Hallek, M., Huellein, J., Matutes, E., Duerig, J., von Kalle, C., Glimm, H., Froehling, S., Abdel-Wahab, O., Hutter, B., Steurer, M., Ho, A., and Zenz, T.

Published
2015

39. High resolution cytogenetic mapping and whole exome sequencing reveal a complex pattern of chromosome 6p aberrations in patients with myeloid malignancies

Author

Pudja, A., Milosević, J. D., Klampfl, T., Harutyunyan, A., Berg, T., Bagienski, K., Chen, D., Gisslinger, B., Rumi, E., Malcovati, L., Pietra, Daniela, Elena, C., Della Porta, M. G., Pieri, Lisa, Guglielmelli, Paola, Doubek, M., Dvorakova, D., Suvajdžić, Nada, Tomin, D., Tošić, Nataša, Racil, Z., Steurer, M., Pavlović, Sonja, Vannucchi, A. M., Cazzola, M., Gisslinger, H., Kralovics, R., Pudja, A., Milosević, J. D., Klampfl, T., Harutyunyan, A., Berg, T., Bagienski, K., Chen, D., Gisslinger, B., Rumi, E., Malcovati, L., Pietra, Daniela, Elena, C., Della Porta, M. G., Pieri, Lisa, Guglielmelli, Paola, Doubek, M., Dvorakova, D., Suvajdžić, Nada, Tomin, D., Tošić, Nataša, Racil, Z., Steurer, M., Pavlović, Sonja, Vannucchi, A. M., Cazzola, M., Gisslinger, H., and Kralovics, R.

Published
2015

41. A New GPS-based Digital Protection System for Smart Grids in Loop Structure.

Author

Liu, X., Steurer, M., and Yu, M.

Subjects
SMART power grids, MICROCONTROLLERS, GLOBAL Positioning System, DIGITAL technology, ETHERNET
Abstract

This paper presents a new digital protection system to solve the protection challenges in future smart grids, i.e., fast protection and fault isolation in a loop-structured system with limited magnitude of fault current. The new system combines two protection algorithms, i.e., a differential protection as the primary algorithm and an overcurrent protection as the backup one. The new system uses real-time Ethernet and digital data acquisition techniques to overcome the restriction on data transmission over large grids. The current measurements at different locations are time-synchronized by GPS clocks, and then transmitted to a central computer via the Ethernet. As opposed to digital relays which often contain PMU functionality nowadays, this approach uses time stamps on the instantaneous current values. We build a prototype of the new system on a test-bed. The results from simulations and experiments have demonstrated that the protection system achieves fast and accurate protection. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results